Can Hip Osteoarthritis Be Reversed? What the Evidence Actually Shows

At a Glance

The "cartilage doesn't grow back" answer rests on a real, settled fact — but most hip OA advice never explains why that fact exists, or what it does and doesn't rule out.
Cartilage has almost no blood supply of its own, and the guideline reviews behind the flat "no" were built almost entirely on oral glucosamine pills — a route that loses a substantial share before it ever reaches circulation, on top of cartilage already being hard to nourish once it gets there.
In a peer-reviewed trial, a micellar glucosamine cream applied to the knee — not yet tested in the hip specifically — showed a significant increase in measured joint space width over 12 weeks. That's the opposite of how osteoarthritis usually goes.
The hip sits deeper under muscle than the knee, which sounds like a reason topical support wouldn't apply — but the actual mechanism doesn't depend on how far a product travels locally through skin. It depends on how much glucosamine enters the bloodstream in the first place, and from there, circulation reaches the hip the same way it reaches any joint.

Osteoarthritis of the Hip: What's Actually Happening
Risk Factors for Hip Osteoarthritis
Hip and Knee: Why These Weight-Bearing Joints Behave Similarly
Is It Osteoarthritis, Rheumatoid Arthritis, or Psoriatic Arthritis?
What the "No" Is Actually Built On
The Fact Almost Nobody Mentions
What the Guidelines Were Really Testing
The Result That Points the Other Way
The Evidence, Stacking Up
Wait — Why Haven't You Heard of URAH?
The Honest Bottom Line
Lifestyle Changes and Treatment Options That Can Still Help
Walking Aids and Assistive Support
When Joint Replacement Surgery Becomes the Right Option
What We Carry at Umicellar
FAQ
Further Reading
References

Osteoarthritis of the Hip: What's Actually Happening

Osteoarthritis is the most common form of arthritis, and the hip joint is one of the two weight-bearing joints — alongside the knee — most frequently affected. It happens when the cartilage cushioning the hip joint gradually wears down over time, eventually allowing the bones to rub against each other. This produces the classic pain and stiffness, along with joint damage that shows up on X-ray as narrowing of the space between the ball and socket of the hip joint.

Unlike inflammatory forms of arthritis, hip osteoarthritis isn't primarily driven by immune system activity — it's a degenerative process shaped by genetics, anatomy, prior injury, and activity history. That distinction matters because it changes what actually helps.

Risk Factors for Hip Osteoarthritis

Several risk factors increase the likelihood of developing hip osteoarthritis:

Age — risk increases steadily over time, particularly after 50
Family history — genetic predisposition plays a real role
Hip dysplasia or other anatomical variations present from birth
Previous hip injury or joint trauma
Excess body weight, which increases load on the joint over years
Occupations or activities involving repetitive heavy loading of the hip

Having a risk factor doesn't guarantee hip osteoarthritis will develop — it simply means paying closer attention if hip pain or stiffness appears.

Hip and Knee: Why These Weight-Bearing Joints Behave Similarly

Hip and knee osteoarthritis are frequently discussed together, and for good reason — both are large, weight-bearing joints subjected to years of mechanical load, and both develop osteoarthritis through the same underlying process: cartilage breakdown from cumulative stress rather than autoimmune attack. This shared mechanism is part of why lifestyle interventions that help one — weight loss, low-impact exercise, muscle strengthening — tend to help the other as well.

Where they differ is depth and accessibility. The knee sits close to the skin's surface, while the hip joint is positioned considerably deeper, surrounded by some of the body's largest muscle groups. That difference matters for one specific question — whether a topical product can plausibly reach the hip at all — and it's worth addressing head-on rather than glossing over, which is what the rest of this article does.

Is It Osteoarthritis, Rheumatoid Arthritis, or Psoriatic Arthritis?

Hip pain isn't always osteoarthritis, and it's worth ruling out other causes before assuming it is:

Osteoarthritis — a degenerative joint condition shaped by mechanical load, cartilage breakdown, bone changes, genetics, and injury history, typically affecting one hip more than the other, worsening with activity and improving with rest, most common with increasing age.

Rheumatoid arthritis — an autoimmune condition where the immune system attacks the joint lining. Usually affects multiple joints, often symmetrically, with morning stiffness lasting 30+ minutes and visible inflammation. Requires disease-modifying medication, not just joint-focused management.

Psoriatic arthritis — an autoimmune condition linked to psoriasis, which can affect the hip along with other joints. Often comes with nail changes, skin plaques, and a pattern of joint involvement that can look different from typical osteoarthritis.

If your hip pain came with symmetrical joint involvement, prolonged morning stiffness, skin changes, or a family history of autoimmune disease, that's worth raising with a healthcare professional rather than assuming it's simple wear and tear. A physical exam, combined with imaging and sometimes blood tests, usually clarifies which type of arthritis is involved — and the distinction changes the entire treatment approach.

What the "No" Is Actually Built On

The flat "no" comes from somewhere real. Cartilage is famously bad at healing itself, and once it's broken down in the hip — or any joint — no non-surgical treatment reliably rebuilds it. That's a fair, settled verdict, and major guideline bodies like NICE and the ACR/Arthritis Foundation have reviewed the evidence and reached it.

But a verdict is only as good as the question it was testing. And the studies behind most of those reviews were almost all built around one specific, narrower question: does swallowing glucosamine as a pill measurably help hip and knee osteoarthritis? That's a different question from "can the joint be supported at all" — and the gap between those two questions is where the rest of this section lives.

The Fact Almost Nobody Mentions

Most of your body is fed by blood. Nutrients arrive, waste leaves, and anything you swallow that reaches your bloodstream gets a shot at those tissues.

Cartilage is the odd one out. It has almost no blood supply of its own — it's fed slowly and indirectly, through the squeeze-and-release of the joint as you move, soaking fluid in and out like a sponge. This is true of every joint's cartilage, hip included.

Sit with that for a second, because it changes how you should read the guideline verdict above. Circulation still matters — it's how anything you take eventually reaches the joint area at all. But because cartilage isn't fed by direct blood vessels the way most tissue is, how much of an ingredient actually reaches the bloodstream in the first place becomes a much bigger question than it would be for muscle or skin. And oral glucosamine loses a substantial share before it ever gets there — broken down in the gut, filtered by the liver, before whatever survives even enters circulation. That's a limitation stacking on top of cartilage's own poor blood supply, not a separate problem.

What the Guidelines Were Really Testing

This is the part that flips the story.

When NICE and the ACR reviewed glucosamine for hip and knee osteoarthritis, they were reviewing pill studies — oral glucosamine, taken as a tablet, evaluated on whether enough of it survived the trip to make a measurable difference. That's a completely reasonable thing to test, and the guideline verdict on that specific route is fair.

But it's testing the method, not settling the question of whether the ingredient could ever help if it actually reached the joint in meaningful amounts. If most of the ingredient never survives the gut and liver in the first place, a disappointing pill trial doesn't tell you much about what happens when that limitation is removed.

Which leads to the obvious next question: what happens when you change the delivery method so more of it reaches circulation to begin with — and does that change anything for a joint as deep as the hip?

The Result That Points the Other Way

In a peer-reviewed study published in the Hong Kong Physiotherapy Journal, researchers looked at glucosamine delivered not as a pill, but through the skin — a micellar glucosamine cream (the product was URAH) applied to the knees of osteoarthritis patients over 12 weeks.

One result stands out. Massaging the cream into the joint produced a significant increase in measured joint space width. On X-ray, the gap went from 0.49 mm to 0.79 mm — about a 61% increase.

Joint space width is an indirect measure of cartilage thickness — the standard way osteoarthritis is tracked on X-ray. Here's why that result is worth pausing on: in osteoarthritis, joint space almost always goes one way — it narrows, year after year, as the joint wears down. A study showing it getting wider points the opposite way to the disease.

Now the fair caveats, because you deserve them: this was one study, conducted in the knee, not the hip. Joint space is affected by more than cartilage alone, and a wider gap is consistent with better joint structure rather than hard proof that cartilage grew back. More research — ideally in the hip specifically — is needed to confirm what's happening at the tissue level in that joint. We'll say that plainly instead of dressing it up.

But notice what just happened. The flat "no" was built on pill studies testing a route that loses most of its cargo before reaching circulation. Change the method, and the needle moves the wrong way for the disease — in the joint where it's actually been studied. That's not a proven result for the hip. It's a result the guideline reviews never had room to test.

The Evidence, Stacking Up

One study rarely settles anything, so it matters that this doesn't stand alone.

The delivery gap is measurable. In published absorption research, the through-the-skin route reached up to 10x the glucosamine uptake of the pill — measured directly in the bloodstream, addressing the gut-and-liver loss described above.
This is why hip depth doesn't rule it out. Because the advantage comes from how much glucosamine enters systemic circulation in the first place — not from how far a cream has to travel locally through skin — it isn't a "shallow joints only" mechanism. Once glucosamine is in the bloodstream in meaningfully higher amounts, it reaches joints via normal circulation, hip included. This is different from claiming the cream diffuses all the way to the hip through skin and muscle, which isn't what's being claimed here.
Over 15 years of real-world use. URAH has been recommended in hospitals and clinics for over 15 years, used by more than a million people (the company's figure), with a long safety record and hundreds of verified reviews.

No single one of these proves reversal in hip osteoarthritis specifically. Together, they're harder to dismiss: a consistent direction of travel across the science, the measurements, and real-world use.

Wait — Why Haven't You Heard of URAH?

If something this interesting existed, you'd have heard of it. Right?

It's a fair question, and the answer is reassuring once you know it. URAH isn't a new product chasing a trend. It came out of a Singapore research lab, started by a scientist, Dr. Jonathan Obaje, who found a way to hold a high dose of glucosamine in a stable formula that could carry it through the skin. He built an early version, wasn't happy with it, and kept refining — releasing the advanced micellar formula in 2009 and improving it ever since. The delivery technology is patented in the US, Japan, and Singapore, and an orthopaedic surgeon serves as clinical advisor.

So why isn't it a household name? Because the company spent its money on the science, not the advertising — showing clinical data to doctors, who then recommended it to patients, rather than buying billboards. That's why it turns up in hospital and clinic pharmacies but rarely anywhere louder.

The Honest Bottom Line

Can hip osteoarthritis be reversed?

Not as a guaranteed cure — and anyone promising that is selling you something. What the evidence honestly supports is narrower, and frankly more interesting: the guideline reviews behind the flat "no" were built on oral pills, a route that loses a substantial share before it ever reaches circulation, on top of cartilage already being difficult to nourish once it gets there. Change the delivery method, and the limited evidence we have — from a study in the knee, not yet the hip — starts pointing the other way.

It's not proven for the hip specifically. It's promising, and worth taking seriously as part of a broader plan. When used alongside physical therapy, weight management, and medical care, a consistent 4–12 week trial is a relatively low-risk way to see whether daily topical support belongs in your routine.

Separately from all of this: the word "irreversible" can sound like the conversation is over. It isn't. Small improvements in strength, walking tolerance, pain control, and daily stiffness can make a major difference to how independent and active someone feels — even without the underlying cartilage damage changing, and regardless of where you land on the delivery question above.

Lifestyle Changes and Treatment Options That Can Still Help

Weight management is one of the highest-leverage interventions for hip osteoarthritis. Every pound of excess body weight adds measurable load to the hip with each step, and even modest weight loss can meaningfully reduce pain over time.

Physical therapy builds the muscles supporting the hip joint — particularly the glutes and hip stabilizers — which helps redistribute load away from damaged cartilage and can meaningfully reduce pain and stiffness.

Low-impact exercise — swimming, cycling, and walking — maintains joint mobility and muscle strength without the high-impact loading that aggravates the affected joint. Avoiding activity entirely tends to make hip OA worse, not better, since supporting muscles weaken.

Pain management — topical NSAIDs are strongly established for knee OA and may be considered for other joints, but the hip is deeper and the evidence for topical application is less direct there. Oral NSAIDs can help with hip OA pain but carry gastrointestinal, kidney, liver, and cardiovascular risks, so they're generally best used at the lowest effective dose for the shortest appropriate time, and discussed with a clinician if used regularly. Acetaminophen/paracetamol has a modest effect for mild pain and is generally well tolerated short-term.

Injections — corticosteroid injections may provide short-term relief for hip OA flares, especially when pain is limiting rehabilitation or daily movement. They're not a long-term solution, and effects are usually temporary. Hyaluronic acid (viscosupplementation) injections are discussed more often for knee OA — major guidelines generally recommend against them for hip OA specifically, so they should only be considered, if at all, under specialist guidance rather than assumed to work the same way they sometimes do for the knee.

Walking Aids and Assistive Support

A cane or walking aid, used on the side opposite the affected hip, can meaningfully reduce load on the joint during daily activity — this isn't a sign of "giving in" to the condition, but a practical way to protect the joint while other conservative measures take effect. Many people are hesitant to use a walking aid out of self-consciousness, but reducing joint stress early tends to preserve function longer than pushing through pain.

When Joint Replacement Surgery Becomes the Right Option

Joint replacement surgery isn't the first step for most people with hip osteoarthritis, and for many, it's never needed at all. It becomes the right option when:

Pain significantly limits daily activities (walking, sleeping, personal care) despite structured conservative care over several months
Joint damage has progressed to the point where non-surgical options no longer provide adequate relief
Quality of life is persistently and significantly affected

This isn't a decision to rush into, but it also isn't one to avoid indefinitely once conservative options have been genuinely exhausted — the goal is making that decision at the right time, from an informed position.

What We Carry at Umicellar

If the delivery problem is the real story behind joint supplements, then the answer is a product built to solve it.

URAH Joint Health Omega-3 is rubbed directly onto the affected joint, using a micellar system designed to carry glucosamine through the skin rather than relying on the gut and liver bottleneck that limits oral supplements before they reach the bloodstream. It's the same cream used in the knee OA trial that recorded the increase in joint space width. Apply a small amount over the hip once or twice daily and give it a fair 4–12 week window — this is daily joint support, not instant relief, so consistency is the point.

It comes with over 15 years of use in hospitals and clinics, a long safety record, hundreds of verified reviews, and a 60-day money-back guarantee.

Explore URAH Joint Health Omega-3 →

FAQ

Can hip osteoarthritis really be reversed?

There's no guaranteed cure, and any claim of one should be treated with suspicion. But the evidence is more nuanced than the flat "no": the guideline reviews behind that answer were built on oral glucosamine pills, which lose a substantial share before they ever reach the bloodstream, on top of cartilage already being difficult to nourish once they get there. When glucosamine is delivered through the skin instead, the limited evidence — including a significant increase in joint space width in a peer-reviewed knee OA trial — points in a more hopeful direction. That result hasn't yet been replicated in the hip specifically.

Can severe hip osteoarthritis be reversed?

No structural reversal is proven regardless of severity. Even in advanced cases, the realistic goal is managing symptoms and preserving function, with joint replacement surgery becoming the appropriate option when conservative care is no longer enough.

Is hip osteoarthritis hereditary?

Genetics play a real role, particularly through inherited joint anatomy, hip dysplasia, and general predisposition to cartilage breakdown — though lifestyle factors like weight and activity history also meaningfully affect risk.

What makes hip osteoarthritis worse?

High-impact activity, excess body weight, prolonged inactivity leading to muscle weakness around the joint, and ignoring early symptoms can all accelerate progression or worsen flares.

What causes hip osteoarthritis to flare up?

Hip OA can flare after too much high-impact activity, prolonged walking beyond your current tolerance, sudden increases in exercise, weight gain, poor sleep, or long periods of inactivity that weaken the supporting muscles. The goal isn't complete rest — it's finding the right level of movement and support.

Can hip osteoarthritis be debilitating?

Yes. Advanced hip OA can significantly affect walking, sleep, independence, and quality of life. That's why conservative care should be taken seriously early on, and why joint replacement becomes appropriate when pain and function remain severely limited despite structured management.

Why haven't I heard of URAH before?

URAH has grown through clinical recommendation rather than mass advertising — used in hospitals and clinics for over 15 years, with its research shared directly with doctors rather than promoted through consumer marketing.

References

AAOS OrthoInfo. Osteoarthritis of the Hip.
Johns Hopkins Medicine. Hip Arthritis.
NICE. Osteoarthritis in over 16s: diagnosis and management (NICE guideline).
Kolasinski SL, et al. 2019 ACR/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee.
Brown University Health. Can Hip or Knee Arthritis Be Reversed?
Onigbinde AT, et al. Symptoms-modifying effects of electromotive administration of glucosamine sulphate among patients with knee osteoarthritis. Hong Kong Physiotherapy Journal, 2018.
Umicellar / URAH. Peer-reviewed knee osteoarthritis joint space width study; oral vs. transdermal glucosamine bloodstream absorption comparison (brand-hosted research). umicellar.com/pages/research

Medical Disclaimer: This article is for information only and isn't a substitute for professional medical advice. It doesn't claim that any product cures, reverses, or regrows cartilage, or that the knee OA results described apply directly to the hip. Always check with a healthcare professional before starting any supplement or changing your treatment, and don't delay recommended care.